Optimization of a preclinical therapy of cannabinoids in combination with temozolomide against glioma
- 18 August 2018
- journal article
- research article
- Published by Elsevier BV in Biochemical Pharmacology
- Vol. 157, 275-284
- https://doi.org/10.1016/j.bcp.2018.08.023
Abstract
No abstract availableKeywords
Funding Information
- Instituto de Salud Carlos III
- European Regional Development Fund
- Spanish Ministry of Economy and Competitiveness
- GW Pharma Ltd
- Comunidad de Madrid
- Fundación Mutua Madrileña (AP101042012)
This publication has 46 references indexed in Scilit:
- Local Delivery of Cannabinoid-Loaded Microparticles Inhibits Tumor Growth in a Murine Xenograft Model of Glioblastoma MultiformePLOS ONE, 2013
- Taming THC: potential cannabis synergy and phytocannabinoid‐terpenoid entourage effectsBritish Journal of Pharmacology, 2011
- International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1and CB2Pharmacological Reviews, 2010
- BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factorsBMC Cancer, 2010
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- Cannabidiol Enhances the Inhibitory Effects of Δ9-Tetrahydrocannabinol on Human Glioblastoma Cell Proliferation and SurvivalMolecular Cancer Therapeutics, 2010
- Emerging strategies for exploiting cannabinoid receptor agonists as medicinesBritish Journal of Pharmacology, 2009
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiformeBritish Journal of Cancer, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaThe New England Journal of Medicine, 2005